Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Cancer|June 17, 2022
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)Christian Marth, Miguel Henriques Abreu, Klaus Kaae Andersen, et al.
Journal of Gynecologic Oncology|July 20, 2024
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancerAlexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, et al.
The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial designIgnace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial designIgnace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
Molecular & Cellular Proteomics : MCP|February 15, 2019
Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early DetectionGeorgina D Barnabas, Keren Bahar-Shany, Stav Sapoznik, et al.
Cancer|April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialMansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
The Lancet. Oncology|March 21, 2021
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Anne Floquet, Jonathan A Ledermann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapyAngelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
Pageof 7